ECSP11011099A - Péptidos agonistas de crhr2 y usos de estos - Google Patents

Péptidos agonistas de crhr2 y usos de estos

Info

Publication number
ECSP11011099A
ECSP11011099A EC2011011099A ECSP11011099A ECSP11011099A EC SP11011099 A ECSP11011099 A EC SP11011099A EC 2011011099 A EC2011011099 A EC 2011011099A EC SP11011099 A ECSP11011099 A EC SP11011099A EC SP11011099 A ECSP11011099 A EC SP11011099A
Authority
EC
Ecuador
Prior art keywords
crhr2
treatment
relates
present
peptides
Prior art date
Application number
EC2011011099A
Other languages
English (en)
Inventor
Nigel P Shankley
Ronald V Swanson
Veronica Moreno
Peter Genso
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP11011099A publication Critical patent/ECSP11011099A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)

Abstract

La presente invención se relaciona con péptidos nuevos que son agonistas selectivos del receptor de la hormona de liberación de corticotropina tipo 2 (CRHR2) y las composiciones de éstos para el tratamiento, mejora o inhibición de afecciones cardiovasculares que incluyen, pero sin limitarse a, la insuficiencia cardíaca. El péptido agonista nuevo comprende, preferentemente, modificaciones que incluyen péptidos pegilados. Además, la presente invención se relaciona con los métodos para el tratamiento y prevención de un enfermedad o trastorno relacionado con la actividad deCRHR2.
EC2011011099A 2008-11-04 2011-06-02 Péptidos agonistas de crhr2 y usos de estos ECSP11011099A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11123308P 2008-11-04 2008-11-04
US17889009P 2009-05-15 2009-05-15

Publications (1)

Publication Number Publication Date
ECSP11011099A true ECSP11011099A (es) 2011-07-29

Family

ID=41509080

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011099A ECSP11011099A (es) 2008-11-04 2011-06-02 Péptidos agonistas de crhr2 y usos de estos

Country Status (20)

Country Link
US (1) US10040838B2 (es)
EP (1) EP2362881B1 (es)
JP (1) JP2012508014A (es)
KR (1) KR20110091720A (es)
CN (1) CN102272151B (es)
AU (1) AU2009313619A1 (es)
BR (1) BRPI0921640A2 (es)
CA (1) CA2742710A1 (es)
CO (1) CO6341479A2 (es)
CR (1) CR20110305A (es)
EA (1) EA201170647A1 (es)
EC (1) ECSP11011099A (es)
ES (1) ES2723098T3 (es)
IL (1) IL212685A0 (es)
MX (1) MX2011004718A (es)
NI (1) NI201100087A (es)
NZ (1) NZ592670A (es)
SG (1) SG171957A1 (es)
WO (1) WO2010053990A2 (es)
ZA (1) ZA201104160B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110091720A (ko) 2008-11-04 2011-08-12 얀센 파마슈티카 엔.브이. Ｃｒｈｒ2 펩티드 작용제 및 이의 용도
WO2011057027A2 (en) * 2009-11-04 2011-05-12 Janssen Pharmaceutica Nv Method for treating heart failure with stresscopin-like peptides
PL2814513T3 (pl) 2012-02-14 2018-06-29 The Regents Of The University Of California Układowe dostarczanie i regulowana ekspresja genów parakrynnych w chorobach sercowo-naczyniowych i innych stanach
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69032809T2 (de) 1989-11-06 1999-07-08 Cell Genesys, Inc., Foster City, Calif. Herstellung von Proteinen mittels homologer Rekombination
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
SG47099A1 (en) * 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
RU2305109C2 (ru) 2001-03-15 2007-08-27 Рисерч Дивелопмент Фаундейшн Урокортин iii, его аналог (варианты) и фармацевтическая композиция
ES2268044T3 (es) 2001-05-21 2007-03-16 Injet Digital Aerosols Limited Composiciones para la administracion de proteinas por la via pulmonar.
US7144985B2 (en) * 2001-12-03 2006-12-05 Metabolex, Inc. Methods and reagents for diagnosis and treatment of diabetes
US7192923B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
CN100480267C (zh) * 2002-01-16 2009-04-22 宝洁公司 促肾上腺皮质激素释放因子2受体激动剂
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
WO2005035727A2 (en) 2003-10-09 2005-04-21 Ambrx, Inc. Polymer derivatives
US20080261863A1 (en) * 2004-06-12 2008-10-23 Bayer Pharmaceuticals Corp Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US7815905B2 (en) * 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2009027844A2 (en) 2007-05-25 2009-03-05 Celtic Pharma Management L.P. Crf conjugates with extended half-lives
WO2009040027A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide stresscopin as a therapeutic agent
US9617557B2 (en) 2007-09-14 2017-04-11 Basf Plant Science Gmbh Plants having increased yield-related traits by expressing a growth-regulating factor (GRF) polypeptide and method for making the same
KR20110091720A (ko) 2008-11-04 2011-08-12 얀센 파마슈티카 엔.브이. Ｃｒｈｒ2 펩티드 작용제 및 이의 용도
US20120277158A1 (en) 2009-10-06 2012-11-01 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
WO2011057027A2 (en) * 2009-11-04 2011-05-12 Janssen Pharmaceutica Nv Method for treating heart failure with stresscopin-like peptides
RS61594B1 (sr) 2011-07-18 2021-04-29 The United States Of America As Represented By The Secretary Department Of Health And Human Services Postupci i kompozicije za inhibiranje patologije povezane sa poliomavirusom

Also Published As

Publication number Publication date
US10040838B2 (en) 2018-08-07
CN102272151A (zh) 2011-12-07
WO2010053990A3 (en) 2010-07-01
NZ592670A (en) 2013-01-25
KR20110091720A (ko) 2011-08-12
CA2742710A1 (en) 2010-05-14
NI201100087A (es) 2011-10-25
ZA201104160B (en) 2012-11-28
MX2011004718A (es) 2011-07-28
CN102272151B (zh) 2014-08-20
JP2012508014A (ja) 2012-04-05
US20100130424A1 (en) 2010-05-27
EP2362881A2 (en) 2011-09-07
CR20110305A (es) 2011-11-10
CO6341479A2 (es) 2011-11-21
ES2723098T3 (es) 2019-08-21
IL212685A0 (en) 2011-07-31
EA201170647A1 (ru) 2011-12-30
WO2010053990A2 (en) 2010-05-14
AU2009313619A1 (en) 2010-05-14
BRPI0921640A2 (pt) 2019-09-24
EP2362881B1 (en) 2019-03-13
SG171957A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
ECSP18002929A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
CL2019001552A1 (es) Agonistas duales acilados de glp-1/glp-2.
ECSP11011099A (es) Péptidos agonistas de crhr2 y usos de estos
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
ECSP12011593A (es) Análogos de glucagón acilados
GT200800198A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1.
CL2011001578A1 (es) Anticuerpo que inhibe selectivamente al receptor del peptido relacionado al gen de la calcitonina ( cgrp r) humano; polinucleotido que lo codifica; vector; celula; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar un medicamento para tratar una condicion asociada con cgrp r en un paciente, como migraña.
BR112017008160A2 (pt) peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição.
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
AR069136A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos
UY31619A1 (es) Compuestos espiro como antagonistas del receptor npy y5
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
UY32152A (es) Antagonistas de heteroarilo de receptores de prostaglandina d2
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
EA201100133A1 (ru) Антагонисты рецепторов простагландина d
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
CR20120415A (es) Polipéptidos agonistas que se enlazan a dr5
WO2009095489A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CO6541617A2 (es) Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
CO2023012684A2 (es) Compuestos agonistas beta del receptor de la hormona tiroidea
PT1988914E (pt) Combinação de análogos de somatostatina com diferente selectividade para subtipos do receptor da somatostatina humana